

Synthesis of 2'-Deoxy-5-monofluoromethyluridine (FTDR) and 2'-Deoxy-5-difluoromethyluridine (F₂TDR)


Jasenka Matulic-Adamic and Kyoichi A. Watanabe

Laboratory of Organic Chemistry, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division of Graduate School of Medical Sciences, Cornell University, NY 10021, U.S.A.

The synthesis of potential anticancer and antitumour nucleosides, 2'-deoxy-5-monofluoromethyluridine (FTDR) and 2'-deoxy-5-difluoromethyluridine (F₂TDR) was achieved in four steps from thymidine including monosilylation with t-butyl(diphenyl)silyl chloride, photochemical bromination, followed by AgF treatment and subsequent desilylation.

The synthesis of 2'-deoxyuridine derivatives containing a partially fluorinated methyl group at C-5 has been the subject of extensive studies¹ since the discovery of the antitumour and antiviral activities of 2'-deoxy-5-trifluoromethyluridine or F₃TDR (1; R¹ = R² = H).² 5-Difluoromethyluracil has been prepared and reported to be extremely labile in aqueous

media.¹ All attempts to synthesize 5-monofluoromethyluracil have failed due to instability of the product.¹ It is quite conceivable that the dissociation of H-1 would assist release of fluoride ion from a 5-fluoromethyluracil base. Nucleosides of 5-monofluoromethyluracil or 5-difluoromethyluracil, which do not bear a dissociable proton at N-1, may be reasonably



- (1) R = CF₃ (F₃TDR; R¹ = R² = H)
 (2) R = CH₂F (FTDR; R¹ = R² = H)
 (3) R = CHF₂ (F₂TDR; R¹ = R² = H)
 (4) R = Me
 (5) R = CH₂Br
 (6) R = CHBr₂
 a; R¹ = R² = Acetyl
 b; R¹ = H, R² = SiPh₂But

stable although the aglycons themselves are quite susceptible to hydrolysis. We therefore undertook synthesis of 2'-deoxy-5-monofluoromethyluridine (**2**, R¹ = R² = H) (FTDR) and 2'-deoxy-5-difluoromethyluridine (**3**, R¹ = R² = H) (F₂TDR) from a preformed nucleoside.

Di-*O*-acetylthymidine (**4a**) was converted into the bromomethyl derivative (**5a**) or (**6a**) by photochemical bromination according to the Baerwolff-Langen procedure.³ Treatment of crude (**5a**) with excess of AgF in MeCN for 15 minutes at room temperature afforded di-*O*-acetyl-2'-deoxy-5-monofluoromethyluridine (**2a**) which was purified on a silica gel column (n-hexane-EtOAc 1:1 to 1:2) and crystallized from CH₂Cl₂-Et₂O-petroleum ether, m.p. 24–27 °C (32% yield). The product was analysed correctly for C₁₄H₁₇FN₂O₇, and showed a double doublet for CH₂F at δ 5.19 (*J*_{H,F} = 47.48, *J*_{H,H} = 3.29 Hz). In a similar manner, (**3a**) was obtained as a colourless foam from (**6a**); the CHF₂ signal appeared as a triple doublet at δ 6.69 (*J*_{H,F} = 54.96, *J*_{H,6} = 2.56 Hz). Attempts at de-*O*-acetylation of (**2a**) in base resulted in complete conversion into 2'-deoxy-5-hydroxymethyluridine. Deacetylation in acid was always accompanied by partial

solvolysis of the 5-fluoromethyl group, and isolation of FTDR in a pure state was very difficult. FTDR, m.p. 140 °C (decomp.), was prepared from (**2b**) by desilylation with Buⁿ₄NF in tetrahydrofuran (THF).

The *t*-butyldiphenylsilyl protecting group, however, was found to be suitable for preparation of the unprotected 5-fluoromethyluracil nucleosides, FTDR and F₂TDR, since it is resistant to HBr during the bromination step and is readily removable with Buⁿ₄NF in THF. Selective silylation⁴ of thymidine with *t*-butyldiphenylsilyl chloride in pyridine afforded 5'-*O*-*t*-butyldiphenylsilylthymidine (**4b**), m.p. 170–171 °C, which was brominated under the Baerwolff-Langen conditions. The crude monobromide (**5b**) was directly treated with AgF in MeCN, and the monofluoromethyl product (**2b**) was isolated in 38% yield after preparative t.l.c. purification (n-hexane-EtOAc 1:3) followed by crystallization from CH₂Cl₂-n-hexane; m.p. 129–131 °C, a doublet for CH₂F appeared at δ 4.80 (*J*_{H,F} = 47.92 Hz).

In a similar manner, the protected difluoromethyluracil nucleoside (**3b**), m.p. 156–158 °C, and F₂TDR, m.p. 159–160 °C, were also prepared. Thus, for the first time the synthesis of thymidine analogues containing a partially fluorinated methyl group has been achieved.

We thank Dr. Jack J. Fox of our Institute for his continued interest and the National Cancer Institute, U.S. Department of Health and Human Services for financial support.

Received, 1st July 1985; Com. 931

References

- 1 M. P. Mertes, S. E. Saheb, and D. Miller, *J. Med. Chem.*, 1966, **9**, 876.
- 2 C. Heidelberger, D. G. Parsons, and D. C. Remy, *J. Am. Chem. Soc.*, 1962, **84**, 3597; *J. Med. Chem.*, 1964, **7**, 1.
- 3 D. Baerwolff and P. Langen in 'Nucleic Acid Chemistry,' eds. L. B. Townsend and R. S. Tipson, Wiley-Interscience, New York, 1978, vol. 1, p. 359.
- 4 S. Hanessian and P. Lavalee, *Can. J. Chem.*, 1975, **53**, 2975.